Investigation of heavy metal effects on immobilized paraoxanase by glutaraldehyde

Journal of Enzyme Inhibition and Medicinal Chemistry

Volumn 28, Issue 3, 2013, Pages 440-446

  Bilen, Çiǧdem ^a   Beyaztaş, Serap ^a   Arslan, Oktay ^a   Güler, Özen Özensoy ^a  

^a BALIKESIR UNIVERSITY   (Turkey)

Author keywords

Enzyme immobilization; Enzyme inhibition; Glutaraldehyde; Paraoxonase

Indexed keywords

1 NAPHTHYLAMINE; ARYLDIALKYLPHOSPHATASE; BOVINE SERUM ALBUMIN; COBALT; COPPER; GLUTARALDEHYDE; IMMOBILIZED ENZYME; MANGANESE; PARAOXON; SEPHAROSE; AMINE; BARIUM; CHROMIUM; COPPER DERIVATIVE; EDETIC ACID; GLASS; HEAVY METAL; IMIDAZOLE; IRON; LANTHANUM; LEAD; PHENOL; THIOL; TRYPSIN; TYROSINE; ZINC;

ARTICLE; BINDING AFFINITY; CATALYSIS; CROSS LINKING; ENZYME ACTIVITY; ENZYME IMMOBILIZATION; HYDROPHOBIC INTERACTION CHROMATOGRAPHY; PH; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; TEMPERATURE RELATED PHENOMENA; ANIMAL EXPERIMENT; BACILLUS LICHENIFORMIS; COMPETITIVE INHIBITION; COVALENT BOND; ENZYME INHIBITION; ENZYME SUBSTRATE; GEL; HUMAN; IC50; IN VITRO STUDY; MICHAELIS CONSTANT; NONHUMAN; PROTEIN CROSS LINKING; TEMPERATURE;

1-NAPHTHYLAMINE; ANIMALS; ARYLDIALKYLPHOSPHATASE; CATTLE; ELECTROPHORESIS, POLYACRYLAMIDE GEL; ENZYME INHIBITORS; ENZYMES, IMMOBILIZED; GLUTARAL; HYDROGEN-ION CONCENTRATION; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; KINETICS; METALS, HEAVY; PARAOXON; TYROSINE;

BOVINAE;

EID: 84875397459     PISSN: 14756366     EISSN: 14756374     Source Type: Journal    
DOI: 10.3109/14756366.2011.647007     Document Type: Article

References (42)

1. Sedlacek M, Manoharan I, Boopathy R, Duysen EG, Masson P, Lockridge O. Butyrylcholinesterase, paraoxonase, and albumin esterase, but not carboxylesterase, are present in human plasma. Biochem Pharmacol 2005;70:1673-1684.
2. Polat MF, Nalbantölu B. In vitro esterase activity of carbonic anhydrase on total esterase activity level in serum. Turk J Med Sci 2002;32:299-302.
3. Basaran I, Sinan S, Cakir U, Bulut M, Arslan O, Ozensoy O. In vitro inhibition of cytosolic carbonic anhydrases I and II by some new dihydroxycoumarin compounds. J Enzym Inhib Med Chem 2007;23:1,32-36.
4. Scozzafava A, Mastrolorenzo A, Supuran CT. Carbonic anhydrase inhibitors and activators and their use in therapy. Expert Opin Ther Pat 2006;16:1627-1644.
5. Agrawal S, Tripathi G, Prajnya R, Sinha N, Gilmour A, Bush L et al. Paraoxonase 1 gene polymorphisms contribute to coronary artery disease risk among north Indians. Indian J Med Sci 2009;63:335-344.
6. Turk R, Juretic D, Geres D, Turk N, Rekic B, Simeon-Rudolf V et al. Serum paraoxonase activity and lipid parameters in the early postpartum period of dairy cows. Res Vet Sci 2004;76:57-61.
7. Sorenson RC, Primo-Parmo SL, Kuo CL, Adkins S, Lockridge O, La Du BN. Reconsideration of the catalytic center and mechanism of mammalian paraoxonase/arylesterase. Proc Natl Acad Sci USA 1995;92:7187-7191.
8. Gan KN, Smolen A, Eckerson HW, La Du BN. Purification of human serum paraoxonase/arylesterase. Evidence for one esterase catalyzing both activities. Drug Metab Dispos 1991;19:100-106.
9. Parthasarathy S, Morales AJ, Murphy AA. Antioxidant: A new role for RU-486 and related compounds. J Clin Invest 1994;94:1990-1995.
10. Mertens A, Holvoet P. Oxidized LDL and HDL: Antagonists in atherothrombosis. Belgium: Center for Experimental Surgery and Anesthesiology, Katholieke Universiteit Leuven.
11. Rodrigo L, Gil F, Hernández AF, Pla A. Identification of two rat liver proteins with paraoxonase activity: Biochemical evidence for the identity of paraoxonase and arylesterase. Chem Biol Interact 1999;119-120:263-275.
12. Selek S, Cosar N, Kocyigit A, Erel O, Aksoy N, Gencer M et al. PON1 activity and total oxidant status in patients with active pulmonary tuberculosis. Clin Biochem 2008;41:140-144.
13. Primo-Parmo SL, Sorenson RC, Teiber J, La Du BN. The human serum paraoxonase/arylesterase gene (PON1) is one member of a multigene family. Genom 1996;33:498-507.
14. Mackness M, Mackness B. Paraoxonase 1 and atherosclerosis: Is the gene or the protein more important? Free Radic Biol Med 2004;37:1317-1323.
15. Karakaya A, Ibis S, Kural T, Köse SK, Karakaya AE. Serum paraoxonase activity and phenotype distribution in Turkish subjects with coronary heart disease and its relationship to serum lipids and lipoproteins. Chem Biol Interact 1999;118:193-200.
16. Akçay YD, Sagin FG, Sendag F, Oztekin K, Sozmen EY. Effects of estrogen-only therapy on LDL oxidation in women with hysterectomy: Does paraoxonase genotype play a role? Maturitas 2006;53:325-332.
17. Pola R, Flex A, Ciaburri M, Rovella E, Valiani A, Reali G et al. Responsiveness to cholinesterase inhibitors in Alzheimer's disease: A possible role for the 192 Q/R polymorphism of the PON-1 gene. Neurosci Lett 2005;382:338-341.
18. Richter RJ, Jarvik GP, Furlong CE. Paraoxonase 1 (PON1) status and substrate hydrolysis. Toxicol Appl Pharmacol 2009;235:1-9.
19. Costa LG, Vitalone A, Cole TB, Furlong CE. Modulation of paraoxonase (PON1) activity. Biochem Pharmacol 2005;69:541-550.
20. Alici HA, Ekinci D, Beydemir S. Intravenous anesthetics inhibit human paraoxonase-1 (PON1) activity in vitro and in vivo. Clin Biochem 2008;41:1384-1390.
21. Ikedaa Y, Suehiroa T, Ariia K, Kumonb Y, Hashimotoa K. High glucose induces transactivation of the human paraoxonase 1 gene in hepatocytes. Metabolism 2008;57:1725-1732.
22. Durrington PN, Mackness B, Mackness MI. Paraoxonase and atherosclerosis. Arterioscl Throm Vas 2001;21:473-480.
23. Mackness MI, Mackness B, Durrington PN. Paraoxonase and coronary heart disease. Atheroscler Suppl 2002;3:49-55.
24. Efrat M, Aviram M. Macrophage paraoxonase 1 (PON1) binding sites. Biochem Biophys Res Commun 2008;376:105-110.
25. Rozenberg O, Shiner M, Aviram M, Hayek T. Paraoxonase 1 (PON1) attenuates diabetes development in mice through its antioxidative properties. Free Radic Biol Med 2008;44:1951-1959.
26. Tiwari AK, Prasad P B K T, Kumar KM, Ammini AC, Gupta A et al. Oxidative stress pathway genes and chronic renal insufficiency in Asian Indians with Type 2 diabetes. J Diabetes Complicat 2009;23:102-111.
27. Clarimon J, Eerola J, Hellström O, Tienari PJ, Singleton A. Paraoxonase 1 (PON1) gene polymorphisms and Parkinson's disease in a Finnish population. Neurosci Lett 2004;367:168-170.
28. Jakoby WB. Crystallization as a purification technique. In: Jakoby WB, (ed.). Enzyme Purification and Related Techniques Method Enzymol. 1971; Vol. 22, New York: Academic Press.
29. Arslan O, Beyazta? S, Sinan S. Inhibition of plant growth regulators on paraoxonase activity. FEB 2008;17:1994-1999.
30. Sinan S, Kockar F, Arslan O. Novel purification strategy for human PON1 and inhibition of the activity by cephalosporin and aminoglikozide derived antibiotics. Biochimie 2006;88:565-574.
31. Builder SE. Hydrophobic interaction chromatography, principles and methods. San Francisco: Amersham Pharmacia Biotech, So; 1993.
32. Warren BS, Kusk P, Wolford RG, Hager GL. Purification and stabilization of transcriptionally active glucocorticoid receptor. J Biol Chem 1996;271:11434-11440.
33. Rosenblat M, Karry R, Aviram M. Paraoxonase 1 (PON1) is a more potent antioxidant and stimulant of macrophage cholesterol efflux, when present in HDL than in lipoprotein-deficient serum: Relevance to diabetes. Atherosclerosis 2006;187:74-81.
34. Munson PJ, Rodbard D. An exact correction to the "Cheng- Prusoff" correction. J Recept Res 1988;8:533-546.
35. Huang X. Fluorescence polarization competition assay: The range of resolvable inhibitor potency is limited by the affinity of the fluorescent ligand. J Biomol Screen 2003;8:34-38.
36. Habeeb AJ, Hiramoto R. Reaction of proteins with glutaraldehyde. Arch Biochem Biophys 1968;126:16-26.
37. Migneault I, Dartiguenave C, Bertrand MJ, Waldron KC. Glutaraldehyde: Behavior in aqueous solution, reaction with proteins, and application to enzyme crosslinking. BioTechniques 2004;37:790-796, 798.
38. Ahmed SA, Saleh SA, Abdel-Fattah AF. Stabilization of Bacillus licheniformis ATCC 21415 alkaline protease by immobilization and modification. Australian J Basic Appl Sci 2007;1:313-322.
39. Pellin MC, Moretto A, Lotti M, Vilanova E. Distribution and some biochemical properties of rat paraoxonase activity. Neurotoxicol Teratol 1990;12:611-614.
40. Debord J, Dantoine T, Bollinger JC, Abraham MH, Verneuil B, Merle L. Inhibition of aryesterase by aliphatic alcohols. Chem-Biol Interact 1998;113:105-115.
41. Debord J, Bollinger JC, Merle L, Dantoine T. Inhibition of human serum arylesterase by metal chlorides. J Inorg Biochem 2003;94:1-4.
42. Ekinci D, Beydemir S. Purification of PON1 from human serum and assessment of enzyme kinetics against metal toxicity. Biol Trace Elem Res 2010;135:112-120.